Efficacy and Safety of Upadacitinib Monotherapy in MTX-naive Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY - Forschungsportal der Justus-Liebig-Universität Gießen:

Meeting Abstract

Efficacy and Safety of Upadacitinib Monotherapy in MTX-naive Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY

Autorenliste: Kapetanovic, Meliha; Andersson, Maria; Friedman, Alan; Shaw, Tim; Song, Yanna; Aletaha, Daniel; Buch, Maya H.; Mueller-Ladner, Ulf; Pope, Janet

Jahr der Veröffentlichung: 2019

Zeitschrift: Arthritis & Rheumatology

Bandnummer: 71

ISSN: 2326-5191

eISSN: 2326-5205

Konferenz: Annual Meeting of the American-College-of-Rheumatology/Association-of-Rheumatology-Professionals (ACR/ARP)

Verlag: Wiley

Zitierstile

Harvard-Zitierstil: Kapetanovic, M., Andersson, M., Friedman, A., Shaw, T., Song, Y., Aletaha, D., et al. (2019) Efficacy and Safety of Upadacitinib Monotherapy in MTX-naive Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY, Arthritis & Rheumatology, 71

APA-Zitierstil: Kapetanovic, M., Andersson, M., Friedman, A., Shaw, T., Song, Y., Aletaha, D., Buch, M., Mueller-Ladner, U., & Pope, J. (2019). Efficacy and Safety of Upadacitinib Monotherapy in MTX-naive Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY. Arthritis & Rheumatology. 71.

Nachhaltigkeitsbezüge

3 Gesundheit und Wohlergehen